Segall Bryant & Hamill’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$24.9M Buy
317,924
+19,868
+7% +$1.35M 0.3% 103
2026
Q1
$19.3M Sell
298,056
-9,168
-3% -$646K 0.28% 128
2025
Q4
$20.7M Buy
307,224
+90,655
+42% +$6.1M 0.28% 122
2025
Q3
$15.9M Sell
216,569
-94,261
-30% -$6.26M 0.21% 167
2025
Q2
$16.2M Sell
310,830
-32,341
-9% -$1.84M 0.23% 154
2025
Q1
$21.9M Sell
343,171
-9,932
-3% -$577K 0.34% 96
2024
Q4
$16.9M Sell
353,103
-2,073
-0.6% -$106K 0.23% 132
2024
Q3
$20.3M Buy
355,176
+49,856
+16% +$2.86M 0.28% 111
2024
Q2
$16M Buy
305,320
+35,360
+13% +$1.55M 0.28% 115
2024
Q1
$11M Buy
269,960
+27,490
+11% +$1.03M 0.21% 169
2023
Q4
$8.96M Buy
242,470
+24,065
+11% +$906K 0.17% 200
2023
Q3
$8.34M Sell
218,405
-44,683
-17% -$1.83M 0.1% 242
2023
Q2
$9.49M Buy
263,088
+77,586
+42% +$2.65M 0.1% 242
2023
Q1
$7.08M Sell
185,502
-1,352
-0.7% -$63.4K 0.08% 285
2022
Q4
$10.6M Sell
186,854
-3,853
-2% -$197K 0.12% 210
2022
Q3
$7.54M Buy
+190,707
New +$8.43M 0.09% 254
2018
Q1
Sell
-13,400
Closed -$271K 612
2017
Q4
$271K Hold
13,400
0.01% 508
2017
Q3
$233K Hold
13,400
0.01% 532
2017
Q2
$172K Hold
13,400
﹤0.01% 541
2017
Q1
$174K Sell
13,400
-20,000
-60% -$253K ﹤0.01% 535
2016
Q4
$330K Buy
+33,400
New +$366K 0.01% 460
2014
Q2
Sell
-11,000
Closed -$140K 565
2014
Q1
$140K Buy
+11,000
New +$163K ﹤0.01% 563

Other funds holding HALO

Segall Bryant & Hamill's HALO Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Halozyme (HALO) stake by 6.7% in Q2 2026, buying an estimated $1.35M and bringing the position to 317,924 shares worth $24.9M. The position accounts for 0.3% of the portfolio, ranked #103.

Segall Bryant & Hamill first reported a position in HALO in Q1 2014 and has held it in 22 quarters since. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Segall Bryant & Hamill held 317,924 shares of Halozyme worth $24.9M as of Q2 2026.
  • Segall Bryant & Hamill bought 19,868 Halozyme shares in Q2 2026, an estimated $1.35M.
  • Halozyme made up 0.3% of Segall Bryant & Hamill's portfolio in Q2 2026, its #103 holding.
  • Segall Bryant & Hamill first reported a position in Halozyme in Q1 2014 and has held it in 22 quarters since.
  • 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.